AHB(SH:688639) Tianfeng Securities·2025-06-08 08:25Investment Rating - The investment rating for the company is "Hold" with a downgrade from previous ratings [6][27]. Core Views - The company reported a revenue of 2.18 billion yuan for 2024, representing a year-on-year growth of 12.4%, while the net profit attributable to shareholders decreased by 58% to 190 million yuan [1][11]. - The company is experiencing a decline in profitability due to lower prices of valine, despite an increase in production capacity and sales volume [2][12]. - The company is actively pursuing new projects, which are expected to contribute significantly to revenue growth in 2025 and beyond [3][24]. Financial Performance - In 2024, the company achieved a gross profit of 543 million yuan, down 2.43 billion yuan year-on-year, with a gross margin of 24.9%, a decrease of 15.6 percentage points [3][19]. - The first quarter of 2025 saw a revenue of 687 million yuan, a year-on-year increase of 37.2%, but the net profit attributable to shareholders fell by 41% [11][12]. - The company’s amino acid products generated 1.51 billion yuan in revenue, accounting for 69% of total revenue, with a production volume of 99,400 tons, an increase of 20.7% year-on-year [2][13]. Project Development - The company is advancing several projects, including a 50,000-ton bio-based succinic acid production facility and a 50,000-ton bio-based 1,3-propanediol project, which are expected to provide significant revenue increments in the future [3][24]. - The company has maintained a high level of R&D investment, with R&D expenses reaching 124 million yuan in 2024, an increase of 15 million yuan from the previous year [22]. Valuation Forecast - The projected net profits for the company from 2025 to 2027 are estimated to be 293 million yuan, 371 million yuan, and 418 million yuan respectively, reflecting a downward adjustment from previous estimates [4][27].